Personalized Approach to Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Respect to Molecular Landscape: A Case Report and Literature Review

The term “Diffuse Large B-Cell Lymphoma” (DLBCL) covers an extremely heterogeneous range of aggressive hematological tumors of lymphoid origin. The recommended standard first-line treatment R-CHOP is still the leading therapy for newly diagnosed DLBCL. However, the outcomes of the unified approach to chemotherapy disregarding a high clinical and molecular genetic heterogeneity of this variant of non-Hodgkin lymphoma are evaluated as unsatisfactory. This paper is the first in the Russian Federation to report the personal experience with the use of the combination of R-CHOP regimen as basic therapy and chemotherapeutic agent acalabrutinib, one of Bruton tyrosine kinase inhibitors, with respect to Sanger sequencing results.

• Marat Albertovich Mingalimov City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0002-8491-2140 (unauthenticated)
• E.A. Baryakh City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 ; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993 https://orcid.org/0000-0001-6880-9269 (unauthenticated)
• T.N. Tolstykh City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0001-7308-0927 (unauthenticated)
• A.V. Misyurin City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0003-1349-2879 (unauthenticated)
• L.A. Kesaeva GenoTekhnologiya, 104 Profsoyuznaya ul., Moscow, Russian Federation, 117485 https://orcid.org/0000-0001-8277-8649 (unauthenticated)
• A.S. Mkrtchyan GenoTekhnologiya, 104 Profsoyuznaya ul., Moscow, Russian Federation, 117485 https://orcid.org/0000-0002-0638-213X (unauthenticated)
• A.M. Kovrigina National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167 https://orcid.org/0000-0002-1082-8659 (unauthenticated)
• E.N. Misyurina City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0003-2419-4850 (unauthenticated)
• M.S. Orlova IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0009-0009-6369-5413 (unauthenticated)
• T.S. Chudnova City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0002-8012-1640 (unauthenticated)
• D.D. Ivanova City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0009-0004-3632-9198 (unauthenticated)
• O.L. Kochneva City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0000-0003-1338-8203 (unauthenticated)
• S.S. Andreev City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0000-0002-9147-4636 (unauthenticated)
• K.V. Yatskov City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0000-0003-0125-9068 (unauthenticated)
• I.V. Samsonova City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0000-0002-1228-1765 (unauthenticated)
• M.A. Lysenko City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182 https://orcid.org/0000-0001-6010-7975 (unauthenticated)

1. Ngu H, Takiar R, Phillips T, et al. Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? Am Soc Clin Oncol Educ Book. 2022;42:1–14. doi: 10.1200/EDBK_349307. DOI: https://doi.org/10.1200/EDBK_349307
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. doi: 10.1038/35000501. DOI: https://doi.org/10.1038/35000501
3. Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37(4):551–568.e14. doi: 10.1016/j.ccell.2020.03.015. DOI: https://doi.org/10.1016/j.ccell.2020.03.015
4. Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–78. doi: 10.1182/asheducation-2016.1.366. DOI: https://doi.org/10.1182/asheducation-2016.1.366
5. Hilton LK, Scott DW, Morin RD. Biological heterogeneity in diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):267–76. doi: 10.1053/j.seminhematol.2023.11.006. DOI: https://doi.org/10.1053/j.seminhematol.2023.11.006
6. Danilov AV, Magagnoli M, Matasar MJ. Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. Oncologist. 2022;27(1):57–66. doi: 10.1093/oncolo/oyab004. DOI: https://doi.org/10.1093/oncolo/oyab004
7. Guo L, Lin P, Xiong H, et al. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. Biochim Biophys Acta Rev Cancer. 2018;1869(2):85–96. doi: 10.1016/j.bbcan.2018.01.001. DOI: https://doi.org/10.1016/j.bbcan.2018.01.001
8. Wen R, Wang D. MCD-DLBCL arises from germinal center B cells. Blood. 2022;140(10):1058–9. doi: 10.1182/blood.2022017534. DOI: https://doi.org/10.1182/blood.2022017534
9. Chen R, Zhou D, Wang L, et al. MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072839. doi: 10.1177/20406207211072839. DOI: https://doi.org/10.1177/20406207211072839
10. Alu A, Lei H, Han X, et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15(1):138. doi: 10.1186/s13045-022-01353-w. DOI: https://doi.org/10.1186/s13045-022-01353-w
11. Dong R, Yan Y, Zeng X, et al. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Des Devel Ther. 2022;16:3225–39. doi: 10.2147/DDDT.S377697 DOI: https://doi.org/10.2147/DDDT.S377697
12. Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687–99. doi: 10.1182/blood.2022018818. DOI: https://doi.org/10.1182/blood.2022018818
13. Younes A, Sehn LH, Johnson P, et al. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019;37(15):1285–95. doi: 10.1200/JCO.18.02403. DOI: https://doi.org/10.1200/JCO.18.02403
14. Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–53.e3. doi: 10.1016/j.ccell.2021.10.006. DOI: https://doi.org/10.1016/j.ccell.2021.10.006
15. Zhang MC, Tian S, Fu D, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(10):1705–16.e5. doi: 10.1016/j.ccell.2023.09.004. DOI: https://doi.org/10.1016/j.ccell.2023.09.004
16. Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Mol Ther Oncolytics. 2021;21:158–70. doi: 10.1016/j.omto.2021.03.015. DOI: https://doi.org/10.1016/j.omto.2021.03.015
17. Deng T, Zhang S, Xiao M, et al. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B-cell lymphoma. Cancer Med. 2024;13(4):e7005. doi: 10.1002/cam4.7005. DOI: https://doi.org/10.1002/cam4.7005
18. Xu P-P, Liu T, Li Z, et al. Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: a real-world analysis. J Clin Oncol. 2022;40(16_suppl):e19556. doi: 10.1200/JCO.2022.40.16_suppl.e19556. DOI: https://doi.org/10.1200/JCO.2022.40.16_suppl.e19556
19. Xu P, Fan N, Tian Y, et al. A phase III, randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of orelabrutinib plus R-CHOP versus placebo plus R-CHOP in treatment-naive patients with MCD subtype diffuse large B-cell lymphoma. Blood. 2022;140(Suppl 1):12110. doi: 10.1182/blood-2022-158865. DOI: https://doi.org/10.1182/blood-2022-158865